Akebia - רווח למניה ב-12 החודשים האחרונים AKBA

סמלים רשמיים של חברת Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics (AKBA) has transitioned to commercial expansion following the approval of its anemia drug. This trailing twelve-month EPS chart on GURU.Markets captures this growth, with the indicator reaching -118.60. Sales diversification across Asia, Europe, and the US minimizes patent risks, while a focus on chronic kidney disease therapies ensures stable supplies to clinics.

AKBA: רווח נקי למניה (EPS TTM) Akebia 11.02.2024 - 19.11.2026

Akebia Corp - פילוחים אנליטיים ומדדי מפתח (AKBA)

ניתוח ראשוני של החברה:AKBA - Akebia Therapeutics, Inc.
מוצר עיקרי של Akebia

The implementation of energy-saving systems and emission filtration in Akebia Therapeutics (AKBA) laboratories directly impacts operating expenses, affecting the bottom line. The trend in trailing twelve-month (TTM) net income per share measures the efficiency of business scaling amid tight monetary policy, allowing the EPS YoY TTM growth rate chart to diagnose hidden risks of capital stagnation.